News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. Eyes Pipeline as Key Antidepressant Fades


5/3/2012 7:30:30 AM

Danish drugmaker Lundbeck missed first-quarter profit forecasts as it invests in new medicines to offset a faster-than-expected slide in sales of its top-selling antidepressant, which is losing patent protection. However, the firm said on Wednesday it was sticking to its full-year forecasts, arguing new drugs like Ebixa for Alzheimer's disease, as well as a string of soon-to-be launched treatments, would take up the slack. At 1105 GMT, Lundbeck shares were down 0.5 percent at 111.4 Danish crowns, lagging a 0.5 percent rise in the STOXX Europe 600 healthcare index. The shares have underperformed that index by about 20 percent over the past year.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES